6 Participants Needed

Sintilimab for Angiosarcoma

Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests sintilimab, an immunotherapy drug, in patients with advanced, metastatic, or recurrent angiosarcoma. Sintilimab helps the immune system recognize and attack cancer cells, aiming to control the disease.

Who Is on the Research Team?

Vinod Ravi | MD Anderson Cancer Center

Vinod Ravi, M.D.

Principal Investigator

M.D. Anderson Cancer Center

Are You a Good Fit for This Trial?

Adults with advanced, metastatic, or recurrent angiosarcoma who have tried at least one chemotherapy and can't undergo more. They must be in relatively good health (ECOG <=1), have a measurable cancer lesion, expected to live at least 12 weeks, and agree to use effective contraception. Excluded are those previously treated with certain immunotherapies or suffering from conditions that could interfere with the trial.

Inclusion Criteria

I am using effective birth control and will continue for 6 months after the trial ends.
I've had a bad reaction or my cancer got worse after chemotherapy.
The amount of protein in your urine needs to be low.
See 13 more

Exclusion Criteria

If unsure about my eligibility, I will contact the sponsor with my full medical history.
I have been treated with specific drugs that target the immune system.
I have been on IV nutrition for less than 4 weeks due to severe malnutrition.
See 28 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive sintilimab intravenously every 21 days for up to 24 months

24 months
1 visit every 21 days

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 years
Follow-up at 30 and 90 days, then every 60 days

What Are the Treatments Tested in This Trial?

Interventions

  • Sintilimab
Trial Overview The SiARa study is testing Sintilimab's effectiveness on angiosarcoma that has spread or returned after treatment. This phase II trial aims to see if this monoclonal antibody can help the immune system fight cancer by stopping tumor growth and spread.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Treatment (sintilimab)Experimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security